• Home
  • About
  • Webcasts
  • ‘Enforcement 40’ for 2020
  • Enforcement Hall of Fame
  • Contact
Securities Docket
Securities-Docket-Leaderboard_9Sec
  • Class Actions
  • Criminal
  • Global
  • People
  • SD Insider
  • SEC
  • Video
  • Subscribe by email
  • Subscribe
Browse: Home / 2011 / June / 01 / SAC Faces Probe of Trading in Biotechnology Firm MedImmune

SAC Faces Probe of Trading in Biotechnology Firm MedImmune

By Securities Docket on June 1, 2011, 11:06 am

SAC Capital Advisors LP, one of the nation’s most successful hedge funds, is a focus of a Securities and Exchange Commission investigation into whether traders used inside information to profit from the $15 billion takeover of biotechnology firm MedImmune Inc. in 2007, people familiar with the matter say.

Read more: SAC Faces Probe of Trading in Biotechnology Firm MedImmune — WSJ.com

Blog Widget by LinkWithin

Posted in SEC, Top | Tagged Investigations

« Previous Next »

‘Enforcement 40’ for 2020

Securities-Docket_Medium-Rectangle_CaseStudyArrow

Our Sponsors

Securities-Docket_260x125_14Sec Ankura 260x125

Join Us On LinkedIn

Join the Securities Litigation and Enforcement Group on LinkedIn

Archives

Copyright © 2021 Securities Docket.

Powered by WordPress and Hybrid.